Edgar Filing: INNOVUS PHARMACEUTICALS, INC. - Form 4

INNOVUS PHA Form 4 April 03, 2015	ARMACEUT	ICALS, II	NC.							
FORM 4	1								PPROVAL	
	• UNITED	STATES		RITIES An ashington			E COMMISSIO	N OMB Number:	3235-0287	
Check this box if no longer subject to Section 16. Form 4 or						FICIAL O		Estimated burden hou response	urs per	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Resp	oonses)									
1. Name and Addro MIRZA ZIAD	ess of Reporting	Person <u>*</u>	Symbol INNOV			r Trading EUTICALS	5. Relationship Issuer S, (Chu	of Reporting Per eck all applicabl		
		N. 4° 1 11 \	INC. []	-						
			3. Date of Earliest Transaction (Month/Day/Year) 04/01/2015			Director Officer (giv below)	ve title Oth below)	% Owner her (specify		
				4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
(City)	(State)	(Zip)					Person			
	`	-					Acquired, Disposed		-	
	ransaction Date		Date, if	3. Transactic Code (Instr. 8)	4. Securi onAcquired Disposed (Instr. 3, Amount	(A) or l of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
	. 1	c 1 1	C							
Reminder: Report o	on a separate info	- Tor each Cl	ass of sec	unues bene	Perso infor requi	ons who re nation con red to resp ays a curre	or indirectly. spond to the collect tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab					sposed of, or convertible	Beneficially Owner securities)	d		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8.1
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transact	iorDerivative	Expiration Date	Underlying Securities	De

Edgar Filing: INNOVUS PHARMACEUTICALS, INC. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A or Disposed (D) (Instr. 3, 4, and 5)		/Year)	(Instr. 3 and	4)	Sec (In
				Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Unit	<u>(1)</u>	04/01/2015		А	21,429	(2)	(2)	Common Stock	21,429	\$ (

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
MIRZA ZIAD 9171 TOWN CENTRE DRIVE, STE 440 SAN DIEGO, CA 92122						
Signatures						

/s/ Randy Berholtz, Attorney-in-Fact	04/03/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- (2) The Reporting Person was granted a Restricted Stock Unit award on April 1, 2015 of 21,429 shares, which were fully vested on the date of grant.
- (3) These restricted stock units were granted pursuant to the Issuer's 2014 Equity Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.